KDM6A and plasma cell myeloma: In multiple myeloma (MM), UTX inactivating mutations/deletions were detected in 1.5–4% of patients [16–18] and more frequently in established cell lines [19], suggesting a tumor suppressor role for UTX in MM and its implication in disease progression.